Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase 3 Study Evaluating the Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Next Previous
Search
Trial Profile

Randomized Phase 3 Study Evaluating the Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Gemcitabine; Romidepsin
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation

    • Most Recent Events

    • 03 Jul 2024 Planned End Date changed from 29 Feb 2024 to 31 Mar 2026.
    • 11 Nov 2022 Planned End Date changed from 31 Jan 2023 to 29 Feb 2024.
    • 19 Oct 2022 Planned End Date changed from 14 Jan 2021 to 31 Jan 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top